NPRO Napro Biotherapeutics (MM)

NaPro BioTherapeutics to Present at the Wells Fargo Securities Health Care Conference BOULDER, Colo., March 22 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics, Inc. today announced that Leonard Shaykin, Chairman and Chief Executive Officer of NaPro, will present an overview of the Company's progress and strategy at the Wells Fargo Securities Health Care "Fireside Chats" Conference on Wednesday, March 24, 2004 at 3:15 PM Eastern Time at the St. Regis Hotel in New York City. Wells Fargo will provide a live audio webcast of the presentation, which can be accessed through NaPro's website at http://www.naprobio.com/. A replay of the webcast will be available for 90 days. About NaPro BioTherapeutics NaPro BioTherapeutics, Inc., is a life science company focused on the development of therapies for the treatment of cancer and hereditary disease. Forward Looking Statements The statements in the webcast presentation that are not historical facts are forward-looking statements that represent management's beliefs and assumptions as of the date of the webcast presentation, based on currently available information. Forward-looking statements can be identified by the use of words such as "believes," "intends," "estimates," "may," "will," "should," "anticipates," "expected" or comparable terminology or by discussions of strategy. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it cannot assure that these expectations will prove to be correct. Such statements involve risks and uncertainties including those factors identified under the captions "Risk Factors," "Special Note Regarding Forward Looking Statements" or "Cautionary Note Regarding Forward Looking Statements" in the Company's documents filed from time to time with the SEC, including the Company's Current Report on Form 8-K/A, dated February 11, 2004, and its Annual Report on Form 10-K for the year ending December 31, 2003 filed with the SEC on March 11, 2004. Should one or more of these risks materialize (or the consequences of such a development worsen), or should the underlying assumptions prove incorrect, actual results could differ materially from those forecasted or expected. The Company disclaims any intention or obligation to update publicly or revise such statements whether as a result of new information, future events or otherwise. For further information, please contact L. Robert Cohen, Vice President, Investor Relations of NaPro BioTherapeutics, Inc., +1-212-218-8715. DATASOURCE: NaPro BioTherapeutics, Inc. CONTACT: L. Robert Cohen, Vice President, Investor Relations of NaPro BioTherapeutics, Inc., +1-212-218-8715; or Investors, Lilian Stern of Stern Investor Relations, Inc., +1-212-362-1200, or Media, Peter Steinerman, +1-516-374-3031, both for NaPro BioTherapeutics, Inc. Web site: http://www.naprobio.com/

Copyright